Skip to main content

Advertisement

Table 4 Baseline and 3-month and 6-month tocilizumab therapy evaluation criteria in eight patients with peripheral spondyloarthritis

From: Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? a multicentre retrospective observational study

  Patient 14 Patient 15 Patient 16 Patient 17 Patient 18 Patient 19 Patient 20 Patient 21
DAS28         
   M0 4.02 4.52 5 4.58 5.41 6.2 5.23 4.92
   M3 (absolute value) 2.82 3.85 4.3 2.88 3.18 1.1 5.1 4.70
   M3 EULAR response (yes/no) Yes (good) No Yes (moderate) Yes (good) Yes (good) Yes (remission) No No
   M6 (absolute value) 1.95 4.01 5.34 3.12 NA NA NA NA
   M6 EULAR response (yes/no) Yes (remission) No No Yes (good) NA NA NA NA
ASDAS         
   M0 2.41 4.03 MD MD MD 3.8 3 MD
   M3 (absolute value) 1.50 2.64 MD MD MD 1.35 3.1 MD
   M6 (absolute value) 1.03 2.79 MD MD MD NA NA MD
SJCa         
   M0 7 2 2 0 3 9 4 7
   M3 (absolute value) NA NA NA NA 7 0 3 6
   M6 (absolute value) 0 6 1 0 NA NA NA NA
TJCa         
   M0 7 6 5 5 0 15 7 12
   M3 (absolute value) NA NA NA NA 0 0 6 11
   M6 (absolute value) 2 4 3 8 NA NA NA NA
BASDAI, 0 to 100         
   M0 42 75 NA 79.4 67 48 4.7 NA
   M3 (change from M0; %) -31 -6.7 NA -9 +6 NA -2.1 NA
   M6 (change from M0; %) -59.5 -4.7 NA -32 NA NA NA NA
BASFI, 0 to 100         
   M0 40 72 MD MD 54 70 NA NA
   M3 (change from M0, %) -17.5 -26 MD MD +44 NA NA NA
   M6 (change from M0, %) -12.5 -12.5 MD MD NA NA NA NA
Pain VAS, 0 to 10         
   M0 1.5 7 5 7 7 5 6 8
   M3 (absolute value) 2 8 NA 6 8 1 6.5 6
   M6 (absolute value) 1 9 6 7.5 NA NA NA NA
PGA, 0 to 10         
   M0 1 6 7 7.5 7 5.2 6.5 8
   M3 (absolute value) 3.5 6 MD MD 7 1 6.5 8
   M6 (absolute value) 1.2 6 8 MD NA NA NA NA
CRP (mg/dl)a         
   M0 20.2 17 119 12 112.3 65 4 1
   M3 (absolute value) NA NA NA NA 9.5 1 5 1
   M6 (absolute value) 0.4 0.8 128 1 NA NA NA NA
ESR (mm)a         
   M0 39 22 67 26 103 60 27 7
   M3 (absolute value) NA NA NA NA 8 4 7 8
   M6 (absolute value) 5 7 70 2 NA NA NA NA
  1. ASDAS, Assessment of SpondyloArthritis International Society endorsed disease activity score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; M0, month 0 (baseline); M3, month 3; M6, month 6; NA, not available; MD, missing data; PGA, patient's global assessment of disease activity; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale. aFor SJC, TJC, CRP, and ESR, the table shows only the values at baseline (M0) and at last follow-up (M3 or M6).